PrEP and PEP are medical prevention approaches that help reduce the risk of acquiring human immunodeficiency virus (HIV). Pre-exposure prophylaxis, known as PrEP, is used by people who do not have HIV but may have an increased risk of exposure. Post-exposure prophylaxis, called PEP, is used after a possible exposure to HIV and must be started as soon as possible, within 72 hours. Although both approaches involve antiretroviral medicines, their timing and intended use differ. Understanding eligibility, medication schedules, HIV testing, and medical follow-up helps individuals make informed decisions about HIV prevention and access appropriate healthcare.
Pre-exposure prophylaxis (PrEP) involves taking antiretroviral medication before potential exposure to HIV. It is intended for people who do not have HIV and may benefit from additional protection based on their circumstances. When taken as prescribed, PrEP is highly effective at preventing HIV acquired through sex and injection drug use, although effectiveness depends on the medication and how it is used.
PrEP is available in different forms, including oral tablets and long-acting injections in eligible settings. A healthcare professional can help determine which option is appropriate based on medical history, individual needs, and local availability.
Important points about PrEP include:
Eligibility: PrEP may be suitable for people whose sexual or injection-related circumstances increase their likelihood of HIV exposure.
HIV testing: Testing is necessary before starting PrEP and at recommended intervals during its use.
Medication adherence: Taking medication according to the prescribed schedule is important for maintaining protection.
Medical monitoring: Follow-up appointments may include HIV testing and assessments of kidney function or other health considerations, depending on the medication.
Additional prevention: Condoms can help reduce the risk of other sexually transmitted infections, which PrEP does not prevent.
PrEP does not treat an existing HIV infection. Appropriate testing is essential before starting or continuing a prevention regimen.
Post-exposure prophylaxis (PEP) is a short course of antiretroviral medication used after a possible exposure to HIV. Examples of potential exposures include condom failure during sex, sharing injection equipment, or occupational exposure involving potentially infectious blood.
PEP is time-sensitive because treatment should begin as soon as possible, ideally within 24 hours and no later than 72 hours after a possible exposure. Anyone who may need PEP should seek urgent medical evaluation rather than waiting for symptoms or test results.
Key considerations for PEP include:
Urgent assessment: A healthcare professional evaluates the type of exposure and determines whether PEP is appropriate.
Treatment duration: The usual course lasts 28 days.
Medication adherence: Completing the prescribed course is important for the intended preventive effect.
HIV testing: Initial and follow-up tests help assess HIV status after the exposure.
Follow-up care: Medical appointments may address medication side effects, additional testing, and ongoing prevention needs.
PEP is not a substitute for regular prevention strategies when repeated exposure is likely. A healthcare professional may discuss PrEP as an option for future protection after the immediate exposure has been evaluated.
PrEP and PEP serve different purposes in HIV prevention. PrEP is taken before potential exposure, while PEP is used after a possible exposure and requires urgent attention. Both approaches involve appropriate medical assessment, HIV testing, and adherence to prescribed medication. Understanding their timing, use, and limitations can help individuals access suitable prevention options and make informed decisions about their health.